Unit sales / Recurring service fees / Contract-based pharma services

Tiered / Negotiated / Contract-based

6.8% Gross Margin (Thin (<20%))

Product sales / Services / Licensing

Direct sales force / E-commerce / Third-party distributors

Enterprise (pharmaceutical, biotech, hospitals, research institutions)

Government / Institutional / SMB (academic and research)

Diversified life sciences manufacturer and service provider

Contract research and manufacturing services (CRO/CMO)

Moderate

Linear

Global with significant international presence

Very High

Low

Yes

High

Low

Strong

Partial

High

6.5% Return on Assets (Excellent)

Mixed

Moderate

0.73x Total Debt / Equity (Moderate leverage)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

N-A

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0000097745

TMO

3.4% CapEx / Revenue (Low-CapEx Asset-Light)

Low

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

94

-103301

2026-08-31

2026-10-03T13:43|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

125,000 total; 59,000 Americas (47%), 22,000 Asia-Pacific (18%), 44,000 EMEA (35%)

Moderate

Not named

Fragmented

Laboratory Products and Biopharma Services = 53.8% of revenue

Dividend+Buyback; FY2025: $3.00B buyback + $0.64B dividends

Moderate; tariffs and export controls named; tariffs and FX impacts quantified in Analytical Instruments segment margin decline

Pronounced; Q4 stronger; seasonal products vary quarterly

Affirmed

Moderate

Yes; EPA and state environmental consent orders and remediation

Moderate; unconditional purchase obligations in ordinary course; specific dollar figure not separately quantified

No

ISO 27001

Audit Committee

High; approximately half of cash/operations outside U.S.; significant net investments in foreign subsidiaries

FX forwards on EUR, CAD, GBP, CHF, SEK, SGD, HKD; cross-currency interest rate swaps; no commodity hedging disclosed

0

2

none in window

Unit sales / Recurring service fees / Contract-based pharma services

Tiered / Negotiated / Contract-based

6.8% Gross Margin (Thin (<20%))

Product sales / Services / Licensing

Direct sales force / E-commerce / Third-party distributors

Enterprise (pharmaceutical, biotech, hospitals, research institutions)

Government / Institutional / SMB (academic and research)

Diversified life sciences manufacturer and service provider

Contract research and manufacturing services (CRO/CMO)

Moderate

Linear

Global with significant international presence

Very High

Low

Yes

High

Low

Strong

Partial

High

6.5% Return on Assets (Excellent)

Mixed

Moderate

0.73x Total Debt / Equity (Moderate leverage)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

N-A

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0000097745

TMO

3.4% CapEx / Revenue (Low-CapEx Asset-Light)

Low

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

94

-103301

2026-08-31

2026-10-03T13:43|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

125,000 total; 59,000 Americas (47%), 22,000 Asia-Pacific (18%), 44,000 EMEA (35%)

Moderate

Not named

Fragmented

Laboratory Products and Biopharma Services = 53.8% of revenue

Dividend+Buyback; FY2025: $3.00B buyback + $0.64B dividends

Moderate; tariffs and export controls named; tariffs and FX impacts quantified in Analytical Instruments segment margin decline

Pronounced; Q4 stronger; seasonal products vary quarterly

Affirmed

Moderate

Yes; EPA and state environmental consent orders and remediation

Moderate; unconditional purchase obligations in ordinary course; specific dollar figure not separately quantified

No

ISO 27001

Audit Committee

High; approximately half of cash/operations outside U.S.; significant net investments in foreign subsidiaries

FX forwards on EUR, CAD, GBP, CHF, SEK, SGD, HKD; cross-currency interest rate swaps; no commodity hedging disclosed

0

2

none in window